IART Stock Overview
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.
Integra LifeSciences Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$67.44|
|52 Week High||US$77.40|
|52 Week Low||US$61.85|
|1 Month Change||2.48%|
|3 Month Change||-3.40%|
|1 Year Change||-1.34%|
|3 Year Change||46.70%|
|5 Year Change||63.10%|
|Change since IPO||1,358.16%|
Recent News & Updates
An Intrinsic Calculation For Integra LifeSciences Holdings Corporation (NASDAQ:IART) Suggests It's 21% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Integra LifeSciences...
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
I Ran A Stock Scan For Earnings Growth And Integra LifeSciences Holdings (NASDAQ:IART) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
|IART||US Medical Equipment||US Market|
Return vs Industry: IART underperformed the US Medical Equipment industry which returned 3.8% over the past year.
Return vs Market: IART underperformed the US Market which returned 13.7% over the past year.
|IART Average Weekly Movement||4.7%|
|Medical Equipment Industry Average Movement||8.2%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: IART is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: IART's weekly volatility (5%) has been stable over the past year.
About the Company
|1989||3,700||Jan De Witte||https://www.integralife.com|
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
Integra LifeSciences Holdings Fundamentals Summary
|IART fundamental statistics|
Is IART overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IART income statement (TTM)|
|Cost of Revenue||US$549.81m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 23, 2022
|Earnings per share (EPS)||2.56|
|Net Profit Margin||14.19%|
How did IART perform over the long term?See historical performance and comparison
Is Integra LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IART ($68.79) is trading below our estimate of fair value ($85.42)
Significantly Below Fair Value: IART is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: IART is good value based on its PE Ratio (26.9x) compared to the US Medical Equipment industry average (47.8x).
PE vs Market: IART is poor value based on its PE Ratio (26.9x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: IART is poor value based on its PEG Ratio (3x)
Price to Book Ratio
PB vs Industry: IART's PB Ratio (3.6x) is in line with the US Medical Equipment industry average.
How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IART's forecast earnings growth (8.9% per year) is above the savings rate (2%).
Earnings vs Market: IART's earnings (8.9% per year) are forecast to grow slower than the US market (13% per year).
High Growth Earnings: IART's earnings are forecast to grow, but not significantly.
Revenue vs Market: IART's revenue (6.1% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: IART's revenue (6.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IART's Return on Equity is forecast to be low in 3 years time (14.8%).
How has Integra LifeSciences Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IART has high quality earnings.
Growing Profit Margin: IART's current net profit margins (14.2%) are higher than last year (4.1%).
Past Earnings Growth Analysis
Earnings Trend: IART's earnings have grown significantly by 21.6% per year over the past 5 years.
Accelerating Growth: IART's earnings growth over the past year (283.3%) exceeds its 5-year average (21.6% per year).
Earnings vs Industry: IART earnings growth over the past year (283.3%) exceeded the Medical Equipment industry 51.2%.
Return on Equity
High ROE: IART's Return on Equity (13.3%) is considered low.
How is Integra LifeSciences Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IART's short term assets ($1.1B) exceed its short term liabilities ($332.9M).
Long Term Liabilities: IART's short term assets ($1.1B) do not cover its long term liabilities ($1.8B).
Debt to Equity History and Analysis
Debt Level: IART's net debt to equity ratio (69.6%) is considered high.
Reducing Debt: IART's debt to equity ratio has increased from 83.5% to 98.4% over the past 5 years.
Debt Coverage: IART's debt is well covered by operating cash flow (20.1%).
Interest Coverage: IART's interest payments on its debt are well covered by EBIT (5.8x coverage).
What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IART's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jan De Witte (57 yo)
Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 2021. He had been the Chief Executive Officer at Barco NV since September...
Experienced Management: IART's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: IART's board of directors are considered experienced (8.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IART insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Integra LifeSciences Holdings Corporation's employee growth, exchange listings and data sources
- Name: Integra LifeSciences Holdings Corporation
- Ticker: IART
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$5.826b
- Shares outstanding: 84.70m
- Website: https://www.integralife.com
Number of Employees
- Integra LifeSciences Holdings Corporation
- 1100 Campus Road
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/18 23:14|
|End of Day Share Price||2022/01/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.